ArticleInfection and immunity2005
Oral spore vaccine based on live attenuated nontoxinogenic Bacillus anthracis expressing recombinant mutant protective antigen.
Article in Infection and immunity, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 49 citations in OpenAlex.
- Immunological Evidence of Variation in Exposure and Immune Response toFrontiers in immunology · 2022Article
- A Comprehensive Overview on the Production of Vaccines in Plant-Based Expression Systems and the Scope of Plant Biotechnology to Combat against SARS-CoV-2 Virus Pandemics.Plants (Basel, Switzerland) · 2021Review
- Article
- Next-Generation Bacillus anthracis Live Attenuated Spore Vaccine Based on the htrA(-) (High Temperature Requirement A) Sterne Strain.Scientific reports · 2016Article
- The Exosporium Layer of Bacterial Spores: a Connection to the Environment and the Infected Host.Microbiology and molecular biology reviews : MMBR · 2015Review
- Expression and display of a novel thermostable esterase from Clostridium thermocellum on the surface of Bacillus subtilis using the CotB anchor protein.Journal of industrial microbiology & biotechnology · 2015Article
- Frequent and seasonally variable sublethal anthrax infections are accompanied by short-lived immunity in an endemic system.The Journal of animal ecology · 2014Article
- The role of nuclear technologies in the diagnosis and control of livestock diseases--a review.Tropical animal health and production · 2012Review
- Recombinant anthrax toxin receptor-Fc fusion proteins produced in plants protect rabbits against inhalational anthrax.Antimicrobial agents and chemotherapy · 2011Article
- Anthrax vaccination strategies.Molecular aspects of medicine · 2009Review
- Efficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthrax.Infection and immunity · 2009Article
- Identification of in vivo-expressed immunogenic proteins by serological proteome analysis of the Bacillus anthracis secretome.Infection and immunity · 2007Article
- Microarray analysis of transposon insertion mutations in Bacillus anthracis: global identification of genes required for sporulation and germination.Journal of bacteriology · 2007Article
- Search for Bacillus anthracis potential vaccine candidates by a functional genomic-serologic screen.Infection and immunity · 2006Article
- The International Bacillus anthracis, B. cereus, and B. thuringiensis Conference, "Bacillus-ACT05".Journal of bacteriology · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An attenuated nontoxinogenic nonencapsulated Bacillus anthracis spore vaccine expressing high levels of recombinant mutant protective antigen (PA), which upon subcutaneous immunization provided protection against a lethal B. anthracis challenge, was found to have the potential to serve also as an oral vaccine. Guinea pigs immunized per os with the recombinant spore vaccine were primed to B. anthracis vegetative antigens as well as to PA, yet only a fraction of the animals (30% to 50%) mounted a humoral response to all of these antigens. Protective immunity provided by per os immunization correlated with a threshold level of PA neutralizing antibody titers and was long-lasting. Protection conferred by per os immunization was attained when the vaccine was administered in the sporogenic form, which, unlike the vegetative cells, survived passage through the gastrointestinal tract. A comparison of immunization of unirradiated spores with immunization of gamma-irradiated spores demonstrated that germination and de novo synthesis of PA were prerequisites for mounting an immune protective response. Oral immunization of guinea pigs with attenuated B. anthracis spores resulted in a characteristic anti-PA immunoglobulin isotype profile (immunoglobulin [G1 IgG1] versus IgG2), as well as induction of specific anti-PA secretory IgA, indicating development of mucosal immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.